FTC v. Boehringer Ingelheim Pharmace
Case Number:
16-5356
Court:
Nature of Suit:
Companies
Government Agencies
Sectors & Industries:
-
January 06, 2023
Ahead Of Privilege Arguments, 4 Kavanaugh Rulings To Know
The U.S. Supreme Court will hear arguments Monday about how to interpret the protection for communications containing both legal and nonlegal topics. But don't expect any overt attempt to convince the court — and particularly Justice Brett Kavanaugh — that a competing "one significant purpose" standard is flat wrong. Here, Law360 Pulse breaks down four significant Justice Kavanaugh decisions dealing with the issue.
-
June 19, 2018
DC Circ. Backs Boehringer In FTC Atty-Client Privilege Row
The D.C. Circuit refused to overturn a ruling that communications subpoenaed from Boehringer Ingelheim Pharmaceuticals Inc. during a Federal Trade Commission pay-for-delay investigation are covered by attorney-client privilege, saying Tuesday one of their main purposes was to get legal advice.
-
November 15, 2017
DC Circ. Threads Needle On Docs Privilege In FTC Row
A D.C. Circuit panel pressed lawyers for the Federal Trade Commission and Boehringer Ingelheim on Wednesday to spell out the fine line between attorney-client privilege and unprivileged business materials as the FTC investigates a possible pay-for-delay deal.